NaviGate touts 1st 52mm transcatheter tricuspid valve procedure
NaviGate Cardiac Structures touted this week that its Gate catheter-guided tricuspid atrioventricular valved stent was implanted six weeks ago into a patient’s transplanted heart. The patient’s transplanted heart was failing due to severe tricuspid valve insufficiency. The successful implantation at the Policlinico of the University of Padua, Italy, is the first European-based patient treated with the company’s tricuspid replacement heart valve. Three hours after the procedure, the patient was showing improved renal function, NaviGate reported. Two months after the intervention, the 67-year-old male patient has improved clinically and boasts excellent valvular function, according to the company. This procedure brings the total number of NaviGate tricuspid implant cases that haven’t resulted in death after 30 days to three. The patient received a heart transplant in 1990 for post-ischemic dilated cardiomyopathy, the company said, and had an array of comorbidities. Since the start of this year, he has reportedly had five hospitalizations for heart failure due to severe regurgitation of the tricuspid valve in his transplanted heart. The patient was released five days after he received NaviGate’s replacement heart valve. “This is the first size-52 mm Gate tricuspid AVS implanted, and the first tricuspid valve replacement in a failing transplanted heart in one of the leading cardiac centers in Europe. Our team is working diligently to reach the ...
Aneurysms of the renal arteries are rare, probably under-diagnosed, with an incidence estimated at 0.01%. A size exceeding 20mm and the presence of symptoms such as hypertension represent a therapeutic indication for most authors. Endovascular techniques are used more and more to treat proximal lesions and auto-transplantation is the technique of reference for intra-parenchymatous lesions. However, most hilar, non-intra-parenchymatous lesions can be treated in situ without cooling and with a reasonable clamping time.
The objective of this work was to study the mid-term results of the angioplast y of the renal artery on transplanted kidneys.
Aim: This meta-analysis aimed to update and evaluate evidence from randomized controlled trials of tai chi for patients with chronic heart failure. Method: Both English and Chinese databases were searched from their inception to June 2, 2016 (PubMed, EMBASE, Cochrane Central Register of Controlled Trials for English publications and China Knowledge Resource Integrated, Wanfang, and Weipu databases for Chinese publication). Titles, abstracts, and full-text articles were screened against study inclusion criteria: randomized controlled trials studying tai chi intervention for patients with chronic heart failure. The meta-ana...
Conclusion: This case may illustrate a resemblance in the renal glomerulus basement membrane and retinal pigment epithelium–Bruch membrane complex, because the authors observed deposits of excess monoclonal kappa chains manifesting as extracellular, proteinaceous aggregates on the basement membrane of the glomerulus, and striking, globular subretinal deposits that overlay a thickened retinal pigment epithelium–Bruch membrane complex. The ocular lesions' refractoriness to intravitreal treatments could be attributed to the fact that they represent proteinaceous aggregates similar to those documented in the glomer...
Background: Interatrial shunting (IAS) have been reported to lower left atrial pressure (LAP) in heart failure (HF). However, its quantitative impact on hemodynamics has not been explored. We predicted the impact of IAS on hemodynamics by the framework of circulatory equilibrium. Method: In 4 mongrel dogs, we connected the left and right atrium with centrifugal pump to create IAS and measured hemodynamics. We ligated left coronary arteries to create LHF. We predicted hemodynamic variables from the framework of circulatory equilibrium (Fig. 1) and compared with those measured.
Background: Significance of placental growth factor (PlGF) in acute decompensated heart failure (ADHF) was not clear. Methods: We have studied consecutive 436 patients with ADHF admitted to our department from 2011 through 2014. Of 436 patients, 271 patients measured PlGF levels on day 1 were studied. The primary endpoints were all-cause death and cardiovascular (CV) death.Results: We divided into two groups according to PlGF quartiles. Crude Kaplan-Meier curves revealed that high PlGF group (quartile 4; ≥14.1 pg/ml) had worse prognosis than low PlGF group (quartile 1–3;
Background: Skeletal muscle has recently been identified as an organ that produces and releases cytokines, named “myokines”. Brain derived neurotropic factor (BDNF), a neurotrophic factor family, is one of myokines and plays a key role in regulating survival, growth and maintenance of neurons. We investigated whether serum BDNF level at discharge could predict the prognosis in patients with heart failure ( HF). Methods: We prospectively enrolled 94 patients who were hospitalized for worsening HF and had cardiac rehabilitation.
Background: Soluble ST2 (sST2) is a novel biomarker reflecting myocardial stress and fibrosis. Mineralocorticoid receptor antagonist (MRA) has a potential to improve clinical outcomes in heart failure with preserved ejection fraction (HFpEF), since MRA inhibits progression of myocardial hypertrophy and fibrosis. Aim: To investigate the relationship between sST2 and outcome, and interaction between the effect of MRA and the sST2 level in HFpEF. Methods: 191 patients with acute decompensated HF and EF>50% were prospectively enrolled.
The effects of beta blockers on long-term morbidity and mortality have been established in patients with chronic heart failure with reduced left ventricular function. Among various beta blockers, only carvedilol and bisoprolol are approved by Japanese guidelines for treatment of patients with chronic heart failure. Bisoprolol is highly selectivity for the beta-1 receptor, while carvedilol is a non-selective beta blocker with simultaneous alpha receptor antagonist effects. BNP and NT-proBNP are established biomarkers used in the diagnosis and prognosis of chronic heart failure.